Ascendis Pharma A/S (ASND) Net Income by Year
Ascendis Pharma A/S reported a net loss of $267.6M in fiscal year 2025. The change from the prior fiscal year is not meaningful, because that figure was zero or negative. The table below carries 11 fiscal years, from 2015 to 2025, and the quarters Ascendis Pharma A/S has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
ASND Net Income by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
ASND Net Income by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
What net income means
Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line.
More Ascendis Pharma A/S financials
Frequently Asked Questions
What was Ascendis Pharma A/S's net income in fiscal year 2025?
Ascendis Pharma A/S reported a net loss of $267.6M in fiscal year 2025.
How fast is Ascendis Pharma A/S's net income growing?
Ascendis Pharma A/S (ASND) reported a $391.4M net loss in fiscal year 2024 and a $267.6M net loss in fiscal year 2025. A growth rate is not meaningful here, because the earlier figure was zero or negative.
How has Ascendis Pharma A/S's net income changed over the years?
Across the 11 fiscal years this page covers, Ascendis Pharma A/S (ASND) net income went from -$35.7M in fiscal year 2015 to -$267.6M in fiscal year 2025.
What was Ascendis Pharma A/S's net income in the most recent quarter?
Ascendis Pharma A/S (ASND) reported -$39.4M in net income in Q4 2025. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.
What does net income mean on a financial statement?
Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line. This page lists what Ascendis Pharma A/S (ASND) reported on that line in every period on record.